ABBV · 8-K · 20261005PR000030
Guidance / Outlook
AbbVie Inc. · 2026-10-05 · Importance 62 · Surprise 68 · No source text
AbbVie included $216 million of acquired in-process research and development (IPR&D) and milestones expense in third-quarter and full-year 2026 adjusted diluted EPS guidance. The expense reduced adjusted diluted EPS guidance by $0.11, resulting in a Q3 range of $3.73 to $3.77 versus the previously announced $3.84 to $3.88. Full-year 2026 adjusted diluted EPS guidance is now $13.76 to $13.96, compared with $13.87 to $14.07 previously, while total acquired IPR&D and milestones expense reflected in guidance increased from $1.035 billion to $1.251 billion.
Key facts
- Previously announced guidance excluding Q3 2026 acquired IPR&D and milestones expense for the full-year ended December 31, 2026: Acquired IPR&D and Milestones Expense $1,035. source
- Guidance including Q3 2026 acquired IPR&D and milestones expense for the full-year ended December 31, 2026: Acquired IPR&D and Milestones Expense $1,251. source
- Guidance including Q3 2026 acquired IPR&D and milestones expense for the quarter ended September 30, 2026: Acquired IPR&D and Milestones Expense $216. source
- Previously announced guidance excluding Q3 2026 acquired IPR&D and milestones expense for the quarter ended September 30, 2026: Adjusted Diluted EPS Range low $3.84. source
- Previously announced guidance excluding Q3 2026 acquired IPR&D and milestones expense for the quarter ended September 30, 2026: Adjusted Diluted EPS Range high $3.88. source
- Previously announced guidance excluding Q3 2026 acquired IPR&D and milestones expense for the full-year ended December 31, 2026: Adjusted Diluted EPS Range low $13.87. source
- Previously announced guidance excluding Q3 2026 acquired IPR&D and milestones expense for the full-year ended December 31, 2026: Adjusted Diluted EPS Range high $14.07. source
- Guidance including Q3 2026 acquired IPR&D and milestones expense for the quarter ended September 30, 2026: Adjusted Diluted EPS Range low $3.73. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | committed | -6.3% | Guidance including Q3 2026 acquired IPR&D and milestones expense for the full-year ended December 31, 2026: Acquired IPR&D and Milestones… |
| net_income | negative | committed | -6.3% | Guidance including Q3 2026 acquired IPR&D and milestones expense for the full-year ended December 31, 2026: Acquired IPR&D and Milestones… |